Urofollitropin | |||
Source | urine of menopausal women | ||
Standard |
NMPA |
BP/EP |
|
Definition |
This product is the gonadotropin extracted from the urine of postmenopausal women, which is freeze-dried with lactose as excipient. It mainly contains follicle stimulating hormone (FSH), and almost does not contain luteinizing hormone (LH). |
Dried preparation containing menopausal gonadotrophin obtained from the urine of post-menopausal women. It has follicle-stimulating activity and no or virtually no luteinising activity. |
|
Production |
It is prepared by suitable collection and extraction procedures followed by purification steps. The method of preparation includes steps that have been shown to remove and/or inactivate extraneous agents. In addition, the process is designed to minimise microbial contamination. |
||
Character |
White or almost white powder. Soluble in water. |
Almost white or slightly yellowish powder. Soluble in water. |
|
Identification |
When administered to immature female rats as prescribed in the assay, it causes significantly enlargement of the ovaries of young female rats |
When administered to immature female rats as prescribed in the assay, it causes enlargement of the ovaries. |
|
Test |
Water |
Maximum 5.0 per cent |
Maximum 5.0 per cent |
Residual solvent |
Not more than 0.5% |
_______ |
|
Bacterial endotoxins |
Less than 0.01EU per IU of FSH |
Less than 0.40EU per IU of FSH |
|
PH |
5.5-7.0 |
_______ |
|
Appearance of solution |
The solution is clear and colorless |
_______ |
|
Abnormal endotoxin |
All the animals survive for 48 hours. |
_______ |
|
potency |
FSH |
Not less than 200IU/mg |
Not less than 90IU/mg |
Specific activity |
More than 8500IU/mg.pr |
_______ |
|
Residual luteinising activity |
LH/FSH should be N.M.T 1/60 |
LH/FSH should be N.M.T 1/60 |
|
Microbial limit |
TAMC |
≤102cfu/750IU |
_______ |
TYMC |
≤101cfu/750IU |
_______ | |
Escherichia coli |
Should not be detected |
_______ | |
Virus |
Hbs Ag |
Should be negative |
_______ |
HCV antibodies |
Should be negative |
_______ | |
HIV I+II |
Should be negative |
_______ | |
Storage |
In an airtight container, protected from light, at a temperature of 2 °C to 8 °C. |
In an airtight container, protected from light, at a temperature of 2 °C to 8 °C. |
|
Category |
Gonadotropins |
||
Preparation |
Urofollitropin for injection |
1. It is mainly used in combination with chorionic gonadotropin for anovulatory infertility caused by insufficient gonadotropin secretion (hypothalamic pituitary dysfunction or disharmony). It is generally recommended to be used in cases of ineffective ovulation induction such as clomiphene (CC) or bromocriptine.
2. Combined with chorionic gonadotropin, it is used for the treatment of primary or secondary amenorrhea and ovarian function test.
3. It is used for polycystic ovary syndrome (PCOS), especially for those who are ineffective with clomiphene.
4. In the assisted pregnancy technology, the stimulation of superovulation in normal ovulating women is often used in combination with clomiphene and chorionic gonadotropin to obtain multiple eggs at a time.
5. Combined with chorionic gonadotropin to treat male hypogonadism and infertility, and stimulate spermatogenic function.